数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Joshua Silverman Chairman of the Board of Director 49 120.02万(USD) 未持股 2020-03-13
Ivan Gergel Director 59 未披露 未持股 2020-03-13
Bruce T. Bernstein Director 56 14.06万(USD) 未持股 2020-03-13
William S. Singer Director,Vice-Chairman of the Board 78 14.06万(USD) 未持股 2020-03-13
George Perry Director 66 未披露 未持股 2020-03-13
Jonathan L. Schechter Director 46 未披露 未持股 2020-03-13
Charles S. Ryan Director, Chief Executive Officer 55 未披露 未持股 2020-03-13

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert Weinstein Chief Financial Officer, Treasurer, Secretary and Executive Vice President 60 38.17万(USD) 未持股 2020-03-13
Daniel L. Alkon President, Chief Scientific Officer 77 119.96万(USD) 未持股 2020-03-13
Charles S. Ryan Director, Chief Executive Officer 55 未披露 未持股 2020-03-13

董事简历

中英对照 |  中文 |  英文
Joshua Silverman

Joshua Silverman,现任Iroquois Capital Management, LLC的共同创始人、管理合伙人,这是Advisor to Iroquois Capital LP 、Iroquois Capital Offshore Ltd. (统称Iroquois)的注册投资顾问。他从2003年Iroquois成立之时起,就担任联席首席投资官。2000-2003,他担任商业银行Vertical Ventures, LLC的联席首席投资官。组建Iroquois之前,他曾担任Joele Frank的董事,这是专注于并购业务的精品店咨询公司。此前,他曾担任美国总统的新闻秘书助理。1992年,他在Lehigh University获得学士学位。


Joshua Silverman served as a member of the DropCar Board of Directors since the completion of the business combination with Private DropCar and DC Acquisition Corporation, pursuant to which Private DropCar became a wholly owned subsidiary of WPCS International Incorporated “WPCS”, which then changed its name to DropCar on January 30 2018 (the “2018 Merger”) and, prior to that time, served as a director of WPCS since August 2016 and has continued to serve as a director following the Merger with Private AYRO (as defined and described in “CORPORATE GOVERANCE-Board Composition” below). Mr. Silverman currently serves as the Managing Member of Parkfield Funding LLC. Mr. Silverman was the co-founder and a Principal and Managing Partner of Iroquois Capital Management, LLC (“Iroquois”), an investment advisory firm. Since its inception in 2003 until July 2016 Mr. Silverman served as Co-Chief Investment Officer of Iroquois. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies to solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003 Mr. Silverman served as Co-Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as Assistant Press Secretary to The President of the United States. Mr. Silverman currently serves as a director of Protagenic Therapeutics, Neurotrope, Inc., and TapImmune Inc., all of which are public companies. He previously served as a Director of National Holdings Corporation from July 2014 through August 2016 MGT Capital Investments, Inc. from December 2014 to May 2016 and Alanco Technologies Inc. from March 2016 through August 2016. Mr. Silverman received his B.A. from Lehigh University in 1992.
Joshua Silverman,现任Iroquois Capital Management, LLC的共同创始人、管理合伙人,这是Advisor to Iroquois Capital LP 、Iroquois Capital Offshore Ltd. (统称Iroquois)的注册投资顾问。他从2003年Iroquois成立之时起,就担任联席首席投资官。2000-2003,他担任商业银行Vertical Ventures, LLC的联席首席投资官。组建Iroquois之前,他曾担任Joele Frank的董事,这是专注于并购业务的精品店咨询公司。此前,他曾担任美国总统的新闻秘书助理。1992年,他在Lehigh University获得学士学位。
Joshua Silverman served as a member of the DropCar Board of Directors since the completion of the business combination with Private DropCar and DC Acquisition Corporation, pursuant to which Private DropCar became a wholly owned subsidiary of WPCS International Incorporated “WPCS”, which then changed its name to DropCar on January 30 2018 (the “2018 Merger”) and, prior to that time, served as a director of WPCS since August 2016 and has continued to serve as a director following the Merger with Private AYRO (as defined and described in “CORPORATE GOVERANCE-Board Composition” below). Mr. Silverman currently serves as the Managing Member of Parkfield Funding LLC. Mr. Silverman was the co-founder and a Principal and Managing Partner of Iroquois Capital Management, LLC (“Iroquois”), an investment advisory firm. Since its inception in 2003 until July 2016 Mr. Silverman served as Co-Chief Investment Officer of Iroquois. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies to solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003 Mr. Silverman served as Co-Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as Assistant Press Secretary to The President of the United States. Mr. Silverman currently serves as a director of Protagenic Therapeutics, Neurotrope, Inc., and TapImmune Inc., all of which are public companies. He previously served as a Director of National Holdings Corporation from July 2014 through August 2016 MGT Capital Investments, Inc. from December 2014 to May 2016 and Alanco Technologies Inc. from March 2016 through August 2016. Mr. Silverman received his B.A. from Lehigh University in 1992.
Ivan Gergel
暂无中文简介

Ivan Gergel has served as Managing Partner and Chief Medical Officer of New Rhein Healthcare Investors LLC, a pharmaceutical investment company, since March 2018. Prior to that time, from May 2014 through December 2017 Dr. Gergel served as Chief Medical Officer of Nektar Therapeutics, Inc. Dr. Gergel has worked in pharmaceutical development for over thirty years. He currently serves on the boards of directors of Corium International, Inc., Realm Therapeutics, Inc. and Neuraptive Therapeutics, Inc. Dr. Gergel holds an MBBS MD from the Royal Free Hospital School of Medicine in London and an MBA from the Wharton School of Business at the University of Pennsylvania.
暂无中文简介
Ivan Gergel has served as Managing Partner and Chief Medical Officer of New Rhein Healthcare Investors LLC, a pharmaceutical investment company, since March 2018. Prior to that time, from May 2014 through December 2017 Dr. Gergel served as Chief Medical Officer of Nektar Therapeutics, Inc. Dr. Gergel has worked in pharmaceutical development for over thirty years. He currently serves on the boards of directors of Corium International, Inc., Realm Therapeutics, Inc. and Neuraptive Therapeutics, Inc. Dr. Gergel holds an MBBS MD from the Royal Free Hospital School of Medicine in London and an MBA from the Wharton School of Business at the University of Pennsylvania.
Bruce T. Bernstein

Bruce T. Bernstein2016年2月8日加入我们的董事会。Bernstein先生拥有超过30年的证券从业经验,主要担任两种可供选择的融资基金以及套利策略交易和结构的高级投资组合经理。自2006年起,Bernstein先生曾担任Rockmore Capital, LLC的总裁,峰值资产1.4亿美元的直接投资和贷款基金经理。此前,他曾担任Omicron Capital, LP,的联席总裁。Omicron是总部设在纽约的一家投资公司,2001年加入。Omicron资本专注于公众小盘公司的直接投资和贷款,有2.6亿美元的高峰资产规模管理。加盟Omicron Capital之前,Bernstein先生任职于Fortis Investments Inc.,在那里他是银行全球证券套利业务部的高级副总裁,专门从事股权结构性产品和股权套利,然后担任美国银行自营投资业务的总裁。在Fortis之前,Bernstein先生是Nomura Securities International股本衍生 集团的董事,专注于跨境税收套利、国内股票套利和结构性股权互换。Bernstein先生在Kidder Peabody开始了他的职业生涯,在那里他晋升为财务助理。Bernstein先生还担任 XpresSpa Holdings(总部设在纽约的一家全球领先的机场温泉公司)的董事会成员。Bernstein还担任Summit Digital Health(一家总部设在新泽西州的激光血糖仪经销商)的董事会成员。Bernstein先生持有 City University of New York Baruch的商学士学位。


Bruce T. Bernstein has served as President of Rockmore Capital, LLC since 2006 the manager of a direct investment and lending fund with peak assets under management of $140 million. Previously, he served as Co-President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank’s Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank’s proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross-border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein also serves as a member of the Board of Directors of XpresSpa Holdings, the leading airport spa company in the world, based in New York. Mr. Bernstein is also a member of the board of Summit Digital Health, a laser based blood glucose monitor distributor, based in New Jersey. Mr. Bernstein holds a B.B.A. from City University of New York Baruch.
Bruce T. Bernstein2016年2月8日加入我们的董事会。Bernstein先生拥有超过30年的证券从业经验,主要担任两种可供选择的融资基金以及套利策略交易和结构的高级投资组合经理。自2006年起,Bernstein先生曾担任Rockmore Capital, LLC的总裁,峰值资产1.4亿美元的直接投资和贷款基金经理。此前,他曾担任Omicron Capital, LP,的联席总裁。Omicron是总部设在纽约的一家投资公司,2001年加入。Omicron资本专注于公众小盘公司的直接投资和贷款,有2.6亿美元的高峰资产规模管理。加盟Omicron Capital之前,Bernstein先生任职于Fortis Investments Inc.,在那里他是银行全球证券套利业务部的高级副总裁,专门从事股权结构性产品和股权套利,然后担任美国银行自营投资业务的总裁。在Fortis之前,Bernstein先生是Nomura Securities International股本衍生 集团的董事,专注于跨境税收套利、国内股票套利和结构性股权互换。Bernstein先生在Kidder Peabody开始了他的职业生涯,在那里他晋升为财务助理。Bernstein先生还担任 XpresSpa Holdings(总部设在纽约的一家全球领先的机场温泉公司)的董事会成员。Bernstein还担任Summit Digital Health(一家总部设在新泽西州的激光血糖仪经销商)的董事会成员。Bernstein先生持有 City University of New York Baruch的商学士学位。
Bruce T. Bernstein has served as President of Rockmore Capital, LLC since 2006 the manager of a direct investment and lending fund with peak assets under management of $140 million. Previously, he served as Co-President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank’s Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank’s proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross-border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein also serves as a member of the Board of Directors of XpresSpa Holdings, the leading airport spa company in the world, based in New York. Mr. Bernstein is also a member of the board of Summit Digital Health, a laser based blood glucose monitor distributor, based in New Jersey. Mr. Bernstein holds a B.B.A. from City University of New York Baruch.
William S. Singer
暂无中文简介

William S. Singer served as President of CRE until April 26 2016 and served on its board of directors. He was a partner in the Chicago office of the law firm of Kirkland & Ellis LLP from 1980 until 2006 and has been of counsel to that firm since that time, concentrating his practice on corporate, real estate, and legislative matters. He has been listed in Crain’s Who’s Who in Chicago Business in the 2000 2001 2002 2003 and 2004 editions. Mr. Singer has been prominently active in Chicago public service, serving as an Alderman for several years and as a candidate for Mayoral office.
暂无中文简介
William S. Singer served as President of CRE until April 26 2016 and served on its board of directors. He was a partner in the Chicago office of the law firm of Kirkland & Ellis LLP from 1980 until 2006 and has been of counsel to that firm since that time, concentrating his practice on corporate, real estate, and legislative matters. He has been listed in Crain’s Who’s Who in Chicago Business in the 2000 2001 2002 2003 and 2004 editions. Mr. Singer has been prominently active in Chicago public service, serving as an Alderman for several years and as a candidate for Mayoral office.
George Perry
暂无中文简介

George Perry has served as dean of the College of Sciences and professor of biology at The University of Texas at San Antonio since 2006. He additionally holds the position of Semmes Foundation Distinguished University Chair in Neurobiology. Dr. Perry has served as acting Chief Scientific Officer for Neurotez, Inc., a private company focused on Alzheimer’s disease since 2010 and as a director of Neurotez, Inc. since 2008. Dr. Perry is recognized in the field of Alzheimer’s research, where he has studied amyloidosis, oxidative stress, cytoskeleton, metal homeostasis, cell cycle reentry, and mitochondria. He currently serves as the editor for numerous journals and as editor-in-chief for the Journal of Alzheimer’s Disease. He is a fellow of the American Association for the Advancement of Science, Texas Academy of Science, the Microscopy Society of America, past president of the American Association of Neuropathologists and the Southwestern and Rocky Mountain Division of the American Association for the Advancement of Science, a member of the Dana Alliance for Brain Initiatives, and a Fulbright Senior Specialist. Dr. Perry holds a B.A. in Zoology from the University of California, Santa Barbara and a Ph.D. in Marine Biology from Scripps Institution of Oceanography, University of California at San Diego. He completed his postdoctoral fellowship in the Department of Cell Biology at Baylor College of Medicine.
暂无中文简介
George Perry has served as dean of the College of Sciences and professor of biology at The University of Texas at San Antonio since 2006. He additionally holds the position of Semmes Foundation Distinguished University Chair in Neurobiology. Dr. Perry has served as acting Chief Scientific Officer for Neurotez, Inc., a private company focused on Alzheimer’s disease since 2010 and as a director of Neurotez, Inc. since 2008. Dr. Perry is recognized in the field of Alzheimer’s research, where he has studied amyloidosis, oxidative stress, cytoskeleton, metal homeostasis, cell cycle reentry, and mitochondria. He currently serves as the editor for numerous journals and as editor-in-chief for the Journal of Alzheimer’s Disease. He is a fellow of the American Association for the Advancement of Science, Texas Academy of Science, the Microscopy Society of America, past president of the American Association of Neuropathologists and the Southwestern and Rocky Mountain Division of the American Association for the Advancement of Science, a member of the Dana Alliance for Brain Initiatives, and a Fulbright Senior Specialist. Dr. Perry holds a B.A. in Zoology from the University of California, Santa Barbara and a Ph.D. in Marine Biology from Scripps Institution of Oceanography, University of California at San Diego. He completed his postdoctoral fellowship in the Department of Cell Biology at Baylor College of Medicine.
Jonathan L. Schechter
暂无中文简介

Jonathan L. Schechter has served as the Director of Investment Banking at Chardan Capital Markets, a full service investment bank, since February 2008. He previously served as a director of DropCar, Inc. Mr. Schechter has worked with public companies for over two decades, including ten years of legal experience and eleven years of investment banking experience. He has received formal education in finance and accounting and has extensive experience analyzing and evaluating the financial statements of public companies. Mr. Schechter holds an A.B. in Public Policy/Political Science from Duke University and a J.D. from Fordham University School of Law.
暂无中文简介
Jonathan L. Schechter has served as the Director of Investment Banking at Chardan Capital Markets, a full service investment bank, since February 2008. He previously served as a director of DropCar, Inc. Mr. Schechter has worked with public companies for over two decades, including ten years of legal experience and eleven years of investment banking experience. He has received formal education in finance and accounting and has extensive experience analyzing and evaluating the financial statements of public companies. Mr. Schechter holds an A.B. in Public Policy/Political Science from Duke University and a J.D. from Fordham University School of Law.
Charles S. Ryan

Charles S. Ryan于2011年8月加入董事会。Ryan博士担任森林实验室(Forest Laboratories,Forest)的副总裁与首席知识产权法律顾问,他从2003年开始在该公司任职。Forest是Actavis的全资所有的子公司,其资本市值将近600亿美元,开发并销售多个治疗类别的药物产品,包括中枢神经系统、心血管、抗感染、呼吸、胃肠与疼痛管理药物。Ryan博士拥有超过20年的管理知识产权诉讼各个领域的工作经验,在制药与生物技术行业开展尽职调查与专利诉讼以及商标申请。Ryan博士在纽约州立石溪大学(Stony Brook University)获得口腔生物学与病理学的博士学位,并在西新英格兰大学(Western New England University)获得法学学位。


Charles S. Ryan joined the Company as a Director on December 14 2017 and as Chief Executive Officer on February 15 2018. Dr. Ryan is an experienced executive with an extensive background in pharmaceuticals and biotechnology. Since October 2016 he has served as President and Chief Executive Officer for the Orthobond Corporation, a private company focused on creating proprietary surface modifications for the medical device, biotechnology and pharmaceutical industries to enhance the function of a device or pharmaceutical. He was responsible for providing strategic leadership for the company and managing all internal and external corporate affairs. From March 2015 through May 2016 Dr. Ryan was Vice President and General Counsel at Cold Spring Harbor Laboratory, a preeminent non-profit institution focused in neuroscience, bioinformatics, cancer, genomics and plant biology. In this position, he provided guidance to the organization on business, legal and public policy issues. From 2003 until the acquisition by Actavis plc in 2014 Dr. Ryan was Senior Vice President & Chief Intellectual Property Counsel for Forest Laboratories, a specialty pharmaceutical company in New York. At Forest Laboratories, Dr. Ryan led hundreds of due diligence teams, managed all aspects of patent and trademark litigations, developed cross- functional teams to establish a global strategy for hundreds of products, built and managed the company’s IP team, and recruited, developed and trained executive leaders. Two of the company’s most significant drugs were Lexapro for major depressive disorders and Namenda for moderate to severe Alzheimer’s disease. He began his career in biotechnology with The Collaborative Group, Ltd., a bioscience company providing development, research and manufacturing services to the pharmaceutical and skin care industries, where he was the Vice President, General Counsel from 1998 to 2002. Dr. Ryan also has experience in private law practice, holding positions with Darby & Darby, P.C. and Scully, Scott, Murphy & Presser. He served on the Board of Directors of Applied DNA Sciences, Inc. and BioRestorative Therapies as well as was a Director on the Board of Trustees for The College of Wooster. Also, he previously held board seats with ABS Materials, Inc., Lab21 Inc., GlycoMira Therapeutics, Inc., Forest Laboratory Holdings, Ltd., New York Biotechnology Association, Stony Brook University Medical Center Development Council (Chair), and Western New England University Board of Trustees. Dr. Ryan earned his B.A. in Chemistry from The College of Wooster in 1986 a Ph.D. in Oral Biology and Pathology from Stony Brook University in 1990 and his law degree from Western New England University in 1993.
Charles S. Ryan于2011年8月加入董事会。Ryan博士担任森林实验室(Forest Laboratories,Forest)的副总裁与首席知识产权法律顾问,他从2003年开始在该公司任职。Forest是Actavis的全资所有的子公司,其资本市值将近600亿美元,开发并销售多个治疗类别的药物产品,包括中枢神经系统、心血管、抗感染、呼吸、胃肠与疼痛管理药物。Ryan博士拥有超过20年的管理知识产权诉讼各个领域的工作经验,在制药与生物技术行业开展尽职调查与专利诉讼以及商标申请。Ryan博士在纽约州立石溪大学(Stony Brook University)获得口腔生物学与病理学的博士学位,并在西新英格兰大学(Western New England University)获得法学学位。
Charles S. Ryan joined the Company as a Director on December 14 2017 and as Chief Executive Officer on February 15 2018. Dr. Ryan is an experienced executive with an extensive background in pharmaceuticals and biotechnology. Since October 2016 he has served as President and Chief Executive Officer for the Orthobond Corporation, a private company focused on creating proprietary surface modifications for the medical device, biotechnology and pharmaceutical industries to enhance the function of a device or pharmaceutical. He was responsible for providing strategic leadership for the company and managing all internal and external corporate affairs. From March 2015 through May 2016 Dr. Ryan was Vice President and General Counsel at Cold Spring Harbor Laboratory, a preeminent non-profit institution focused in neuroscience, bioinformatics, cancer, genomics and plant biology. In this position, he provided guidance to the organization on business, legal and public policy issues. From 2003 until the acquisition by Actavis plc in 2014 Dr. Ryan was Senior Vice President & Chief Intellectual Property Counsel for Forest Laboratories, a specialty pharmaceutical company in New York. At Forest Laboratories, Dr. Ryan led hundreds of due diligence teams, managed all aspects of patent and trademark litigations, developed cross- functional teams to establish a global strategy for hundreds of products, built and managed the company’s IP team, and recruited, developed and trained executive leaders. Two of the company’s most significant drugs were Lexapro for major depressive disorders and Namenda for moderate to severe Alzheimer’s disease. He began his career in biotechnology with The Collaborative Group, Ltd., a bioscience company providing development, research and manufacturing services to the pharmaceutical and skin care industries, where he was the Vice President, General Counsel from 1998 to 2002. Dr. Ryan also has experience in private law practice, holding positions with Darby & Darby, P.C. and Scully, Scott, Murphy & Presser. He served on the Board of Directors of Applied DNA Sciences, Inc. and BioRestorative Therapies as well as was a Director on the Board of Trustees for The College of Wooster. Also, he previously held board seats with ABS Materials, Inc., Lab21 Inc., GlycoMira Therapeutics, Inc., Forest Laboratory Holdings, Ltd., New York Biotechnology Association, Stony Brook University Medical Center Development Council (Chair), and Western New England University Board of Trustees. Dr. Ryan earned his B.A. in Chemistry from The College of Wooster in 1986 a Ph.D. in Oral Biology and Pathology from Stony Brook University in 1990 and his law degree from Western New England University in 1993.

高管简历

中英对照 |  中文 |  英文
Robert Weinstein
暂无中文简介

Robert Weinstein joined the Company in June 2013 as its acting Chief Financial Officer. The Company is party to an employment agreement dated as of October 1 2013 with Mr. Weinstein, pursuant to which he serves as the Company’s Chief Financial Officer and Executive Vice President. He has extensive accounting and finance experience, spanning more than 30 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September 2011 to the present, Mr. Weinstein has been an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. From March 2010 to August 2011 he was the Chief Financial Officer of Green Energy Management Services Holdings, Inc., a publicly-traded energy consulting company. From August 2007 to February 2010 Mr. Weinstein served as Chief Financial Officer of Xcorporeal, Inc., a publicly-traded, development-stage medical device company which was sold in March 2010 to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide. Mr. Weinstein also serves as a member of the Board of Directors of XpresSpa Group, Inc. Nasdaq: XSPA, a health and wellness company whose core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products. Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant inactive, and received his BS degree in accounting from the State University of New York at Albany.
暂无中文简介
Robert Weinstein joined the Company in June 2013 as its acting Chief Financial Officer. The Company is party to an employment agreement dated as of October 1 2013 with Mr. Weinstein, pursuant to which he serves as the Company’s Chief Financial Officer and Executive Vice President. He has extensive accounting and finance experience, spanning more than 30 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September 2011 to the present, Mr. Weinstein has been an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. From March 2010 to August 2011 he was the Chief Financial Officer of Green Energy Management Services Holdings, Inc., a publicly-traded energy consulting company. From August 2007 to February 2010 Mr. Weinstein served as Chief Financial Officer of Xcorporeal, Inc., a publicly-traded, development-stage medical device company which was sold in March 2010 to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide. Mr. Weinstein also serves as a member of the Board of Directors of XpresSpa Group, Inc. Nasdaq: XSPA, a health and wellness company whose core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products. Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant inactive, and received his BS degree in accounting from the State University of New York at Albany.
Daniel L. Alkon
暂无中文简介

Daniel L. Alkon was appointed as our President on September 16 2016. Dr. Alkon served as the founding Scientific Director of the original Blanchette Rockefeller Neurosciences Institute now known as CRE from 1999 until September 23 2016. He received his undergraduate degree in chemistry in 1965 at the University of Pennsylvania. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he joined the staff of the National Institutes of Health where during his 30 year career he became a Medical Director in the U.S. Public Health Service at the National Institute for Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. From June 2006 to September 23 2016 Dr. Alkon was the Toyota Chair for Neurodegenerative Disease Research at BRNI. In this position, he and his team conducted multidisciplinary research on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly AD. From October 2000 to September 28 2016 Dr. Alkon was also a Professor at CRE and a Professor of Neurology at West Virginia University.
暂无中文简介
Daniel L. Alkon was appointed as our President on September 16 2016. Dr. Alkon served as the founding Scientific Director of the original Blanchette Rockefeller Neurosciences Institute now known as CRE from 1999 until September 23 2016. He received his undergraduate degree in chemistry in 1965 at the University of Pennsylvania. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mount Sinai Hospital in New York, he joined the staff of the National Institutes of Health where during his 30 year career he became a Medical Director in the U.S. Public Health Service at the National Institute for Neurological Disorders and Strokes and Chief of the Laboratory of Adaptive Systems. From June 2006 to September 23 2016 Dr. Alkon was the Toyota Chair for Neurodegenerative Disease Research at BRNI. In this position, he and his team conducted multidisciplinary research on the molecular and biophysical mechanisms of memory and memory dysfunction in psychiatric and neurological disorders, particularly AD. From October 2000 to September 28 2016 Dr. Alkon was also a Professor at CRE and a Professor of Neurology at West Virginia University.
Charles S. Ryan

Charles S. Ryan于2011年8月加入董事会。Ryan博士担任森林实验室(Forest Laboratories,Forest)的副总裁与首席知识产权法律顾问,他从2003年开始在该公司任职。Forest是Actavis的全资所有的子公司,其资本市值将近600亿美元,开发并销售多个治疗类别的药物产品,包括中枢神经系统、心血管、抗感染、呼吸、胃肠与疼痛管理药物。Ryan博士拥有超过20年的管理知识产权诉讼各个领域的工作经验,在制药与生物技术行业开展尽职调查与专利诉讼以及商标申请。Ryan博士在纽约州立石溪大学(Stony Brook University)获得口腔生物学与病理学的博士学位,并在西新英格兰大学(Western New England University)获得法学学位。


Charles S. Ryan joined the Company as a Director on December 14 2017 and as Chief Executive Officer on February 15 2018. Dr. Ryan is an experienced executive with an extensive background in pharmaceuticals and biotechnology. Since October 2016 he has served as President and Chief Executive Officer for the Orthobond Corporation, a private company focused on creating proprietary surface modifications for the medical device, biotechnology and pharmaceutical industries to enhance the function of a device or pharmaceutical. He was responsible for providing strategic leadership for the company and managing all internal and external corporate affairs. From March 2015 through May 2016 Dr. Ryan was Vice President and General Counsel at Cold Spring Harbor Laboratory, a preeminent non-profit institution focused in neuroscience, bioinformatics, cancer, genomics and plant biology. In this position, he provided guidance to the organization on business, legal and public policy issues. From 2003 until the acquisition by Actavis plc in 2014 Dr. Ryan was Senior Vice President & Chief Intellectual Property Counsel for Forest Laboratories, a specialty pharmaceutical company in New York. At Forest Laboratories, Dr. Ryan led hundreds of due diligence teams, managed all aspects of patent and trademark litigations, developed cross- functional teams to establish a global strategy for hundreds of products, built and managed the company’s IP team, and recruited, developed and trained executive leaders. Two of the company’s most significant drugs were Lexapro for major depressive disorders and Namenda for moderate to severe Alzheimer’s disease. He began his career in biotechnology with The Collaborative Group, Ltd., a bioscience company providing development, research and manufacturing services to the pharmaceutical and skin care industries, where he was the Vice President, General Counsel from 1998 to 2002. Dr. Ryan also has experience in private law practice, holding positions with Darby & Darby, P.C. and Scully, Scott, Murphy & Presser. He served on the Board of Directors of Applied DNA Sciences, Inc. and BioRestorative Therapies as well as was a Director on the Board of Trustees for The College of Wooster. Also, he previously held board seats with ABS Materials, Inc., Lab21 Inc., GlycoMira Therapeutics, Inc., Forest Laboratory Holdings, Ltd., New York Biotechnology Association, Stony Brook University Medical Center Development Council (Chair), and Western New England University Board of Trustees. Dr. Ryan earned his B.A. in Chemistry from The College of Wooster in 1986 a Ph.D. in Oral Biology and Pathology from Stony Brook University in 1990 and his law degree from Western New England University in 1993.
Charles S. Ryan于2011年8月加入董事会。Ryan博士担任森林实验室(Forest Laboratories,Forest)的副总裁与首席知识产权法律顾问,他从2003年开始在该公司任职。Forest是Actavis的全资所有的子公司,其资本市值将近600亿美元,开发并销售多个治疗类别的药物产品,包括中枢神经系统、心血管、抗感染、呼吸、胃肠与疼痛管理药物。Ryan博士拥有超过20年的管理知识产权诉讼各个领域的工作经验,在制药与生物技术行业开展尽职调查与专利诉讼以及商标申请。Ryan博士在纽约州立石溪大学(Stony Brook University)获得口腔生物学与病理学的博士学位,并在西新英格兰大学(Western New England University)获得法学学位。
Charles S. Ryan joined the Company as a Director on December 14 2017 and as Chief Executive Officer on February 15 2018. Dr. Ryan is an experienced executive with an extensive background in pharmaceuticals and biotechnology. Since October 2016 he has served as President and Chief Executive Officer for the Orthobond Corporation, a private company focused on creating proprietary surface modifications for the medical device, biotechnology and pharmaceutical industries to enhance the function of a device or pharmaceutical. He was responsible for providing strategic leadership for the company and managing all internal and external corporate affairs. From March 2015 through May 2016 Dr. Ryan was Vice President and General Counsel at Cold Spring Harbor Laboratory, a preeminent non-profit institution focused in neuroscience, bioinformatics, cancer, genomics and plant biology. In this position, he provided guidance to the organization on business, legal and public policy issues. From 2003 until the acquisition by Actavis plc in 2014 Dr. Ryan was Senior Vice President & Chief Intellectual Property Counsel for Forest Laboratories, a specialty pharmaceutical company in New York. At Forest Laboratories, Dr. Ryan led hundreds of due diligence teams, managed all aspects of patent and trademark litigations, developed cross- functional teams to establish a global strategy for hundreds of products, built and managed the company’s IP team, and recruited, developed and trained executive leaders. Two of the company’s most significant drugs were Lexapro for major depressive disorders and Namenda for moderate to severe Alzheimer’s disease. He began his career in biotechnology with The Collaborative Group, Ltd., a bioscience company providing development, research and manufacturing services to the pharmaceutical and skin care industries, where he was the Vice President, General Counsel from 1998 to 2002. Dr. Ryan also has experience in private law practice, holding positions with Darby & Darby, P.C. and Scully, Scott, Murphy & Presser. He served on the Board of Directors of Applied DNA Sciences, Inc. and BioRestorative Therapies as well as was a Director on the Board of Trustees for The College of Wooster. Also, he previously held board seats with ABS Materials, Inc., Lab21 Inc., GlycoMira Therapeutics, Inc., Forest Laboratory Holdings, Ltd., New York Biotechnology Association, Stony Brook University Medical Center Development Council (Chair), and Western New England University Board of Trustees. Dr. Ryan earned his B.A. in Chemistry from The College of Wooster in 1986 a Ph.D. in Oral Biology and Pathology from Stony Brook University in 1990 and his law degree from Western New England University in 1993.